Participants with gametocytes at day 8, by microscopy · adults and children with malaria being treated with non‐artemisinin treatment
Single dose primaquine at 0.4 to 0.5 mg/kg probably leads to lower participants with gametocytes at day 8, by microscopy compared with no primaquine, with non‐artemisinin partner, (moderate certainty).
1 finding from 1 review
Participants infectious at day 8 · adults and children with malaria being treated with non‐artemisinin treatment
It is very uncertain whether single dose primaquine at 0.75 mg/kg changes participants infectious at day 5 compared with no primaquine, with non‐artemisinin partner, (very low certainty).
2 findings from 1 review
Participants with gametocytes at day 5, by microscopy · adults and children with malaria being treated with non‐artemisinin treatment
Single dose primaquine at 0.75 mg/kg showed no clear difference in participants with gametocytes at day 5, by microscopy compared with no primaquine, with non‐artemisinin partner, (low certainty).
1 finding from 1 review
Participants with gametocytes at day 8, by microscopy · adults and children with malaria being treated with non‐artemisinin treatment
Single dose primaquine at 0.75 mg/kg probably leads to lower participants with gametocytes at day 8, by microscopy compared with no primaquine, with non‐artemisinin partner, (moderate certainty).
1 finding from 1 review
Participants with gametocytes at day 8, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.2 to 0.25 mg/kg leads to lower participants with gametocytes at day 8 by PCR compared with no primaquine, with artemisinin partner, (high certainty).
1 finding from 1 review
Participants with gametocytes at day 8, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.4 to 0.5 mg/kg leads to lower participants with gametocytes at day 8, by PCR compared with no primaquine, with artemisinin partner, (high certainty).
1 finding from 1 review
Presence of PIVKA II at day 5: 0.2 mg IM versus 0.5 mg IM · preterm infants
Higher dose vitamin K showed no clear difference in presence of PIVKA II at day 5: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
1 finding from 1 review
Presence of PIVKA II at day 25: 0.2 mg IM versus 0.5 mg IM · preterm infants
Higher dose vitamin K showed no clear difference in presence of PIVKA II at day 25: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
1 finding from 1 review
Presence of PIVKA II at day 5: 0.2 mg IV versus 0.2 mg IM · preterm infants
Intramuscular vitamin K showed no clear difference in presence of PIVKA II at day 5: 0.2 mg IV versus 0.2 mg IM compared with intravenous vitamin K (low certainty).
1 finding from 1 review
Presence of PIVKA II at day 5: 0.2 mg IV versus 0.5 mg IM · preterm infants
Intramuscular vitamin K showed no clear difference in presence of PIVKA II at day 5: 0.2 mg IV versus 0.5 mg IM compared with intravenous vitamin K (low certainty).
1 finding from 1 review
Presence of PIVKA II at day 25: 0.2 mg IV versus 0.2 mg IM · preterm infants
Intramuscular vitamin K showed no clear difference in presence of PIVKA II at day 25: 0.2 mg IV versus 0.2 mg IM compared with intravenous vitamin K (low certainty).
1 finding from 1 review
Presence of PIVKA II at day 25 ‐ 0.2 mg IV versus 0.5 mg IM · preterm infants
Intramuscular vitamin K showed no clear difference in presence of PIVKA II at day 25 ‐ 0.2 mg IV versus 0.5 mg IM compared with intravenous vitamin K (low certainty).
1 finding from 1 review
Percent of days abstinent · people with co‐occurring depression and alcohol dependence
1 finding from 1 review
Amount of alcohol consumed, short term (3‐6 months) measured using the number of drinks/drinking day (in past week to 30 days) · people with co‐occurring depression and alcohol dependence
1 finding from 1 review
Intervention not reported
Subgroup analysis of infants operated on at less than 70 days of age who did not clear their jaundice by six months after Kasai portoenterostomy · infants with biliary atresia
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Number of standard drinks consumed per day over the last 30 days · concurrent problem alcohol and illicit drug users
1 finding from 1 review
Over 50% less standard drinks per day Timeline follow back · concurrent problem alcohol and illicit drug users
Motivational interviewing (MI) showed no clear difference in greater than 50% reduction in number of standard drinks consumed per… compared with treatment (low certainty).
1 finding from 1 review
Abstinence from alcohol over the last 30 days · concurrent problem alcohol and illicit drug users
Motivational interviewing (MI) showed no clear difference in abstinence from alcohol over the last 30 days compared with treatment (low certainty).
1 finding from 1 review
Number of days with alcohol use · concurrent problem alcohol and illicit drug users
1 finding from 1 review
25% reduction of drinking days in the past 30 days · concurrent problem alcohol and illicit drug users
Brief motivational interviewing (BMI) showed no clear difference in 25% reduction of drinking days in the past 30 days compared with assessment‐only to reduce alcohol consumption (moderate certainty).
1 finding from 1 review